In silico engineering of transaminase variants for enhanced biocatalytic conversion of an ACE inhibitor precursor

Key Points

• Enhanced biocatalytic conversion was achieved using engineered transaminase variants.
• The improvement in conversion rates was up to 75% for specific ACE inhibitor precursors.
• Computational modeling and engineering techniques exposed candidate variants for transaminase function.
• This approach may enable more efficient drug synthesis in biocatalysis applications.